Research programme: interferon-gamma variants - Nautilus BiotechAlternative Names: IFN-gamma variants - Nautilus Biotech
Latest Information Update: 16 Jul 2016
At a glance
- Originator Nautilus Biotech
- Class Interferons
- Mechanism of Action Interferon gamma stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Chronic granulomatous disease; Osteopetrosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteopetrosis in France
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-granulomatous-disease in France
- 01 Jun 2005 Preclinical trials in Osteopetrosis in France (unspecified route)